Julai 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics dan GenScript ProBio sedang dalam proses menandatangani kontrak untuk pembangunan dan pengeluaran plasmid dan vektor virus untuk saluran paip pertama Platform CAR-T Advanced (platform ACT) ACT Therapeutics, yang juga akan ditugaskan untuk menghasilkan bahan mentah untuk saluran paip ACT Therapeutics yang seterusnya. Kontrak itu akan meliputi pengeluaran plasmid dan vektor virus untuk saluran paip pertama Platform CAR-T Advanced ACT Therapeutics.
Hasil daripada perjanjian ini, GenScript ProBio telah dinaikkan kepada status rakan kongsi global yang mampu menyokong platform ACT untuk terapeutik ACT.
Platform ACT ialah teknologi terapi sel dan gen generasi akan datang yang menyasarkan antigen kanser dengan memasukkan gen yang direka untuk menyasarkan antigen tersebut ke dalam sel imun. Gen ini dihantar ke dalam sel imun melalui penggunaan vektor virus. GenScript ProBio mempunyai pembangunan proses vektor virus berkualiti tinggi dan platform perkhidmatan sehenti untuk pengeluaran GMP, yang kedua-duanya diperlukan untuk pembangunan terapi sel dan gen.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing kanser darah. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, Ketua Pegawai Eksekutif ACT Therapeutics, berkata, “Kami telah melengkapkan persediaan untuk platform ACT muncul di peringkat global melalui perkongsian strategik dengan GenScript ProBio. Kami akan mempercepatkan pembangunan rawatan yang menyasarkan kanser pepejal yang tahan api dan sukar dikawal."
Mengenai GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Ke arah misi "Inovasi melalui Kerjasama", GenScript ProBio komited untuk membantu pelanggan memendekkan garis masa untuk pembangunan ubat biologi daripada penemuan kepada pengkomersialan, mengurangkan kos R&D dengan ketara dan membina masa depan yang lebih sihat.
